Imaging of glutamate neurotransmitter alterations in Alzheimer's disease.
NMR Biomed
; 26(4): 386-91, 2013 Apr.
Article
en En
| MEDLINE
| ID: mdl-23045158
ABSTRACT
Glutamate (Glu) is a major excitatory neurotransmitter in the brain and has been shown to decrease in the early stages of Alzheimer's disease (AD). Using a glutamate chemical (amine) exchange saturation transfer (GluCEST) method, we imaged the change in [Glu] in the APP-PS1 transgenic mouse model of AD at high spatial resolution. Compared with wild-type controls, AD mice exhibited a notable reduction in GluCEST contrast (~30%) in all areas of the brain. The change in [Glu] was further validated through (1) H MRS. A positive correlation was observed between GluCEST contrast and (1) H MRS-measured Glu/total creatine ratio. This method potentially provides a novel noninvasive biomarker for the diagnosis of the disease in preclinical stages and enables the development of disease-modifying therapies for AD.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neurotransmisores
/
Ácido Glutámico
/
Enfermedad de Alzheimer
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
NMR Biomed
Asunto de la revista:
DIAGNOSTICO POR IMAGEM
/
MEDICINA NUCLEAR
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos